蛋白酶体抑制剂——硼替佐米的临床治疗研究进展  

Advances in studies on the therapy with proteasome inhibitor Bortezomib

作　　者：王立琳[1] 肖若芝[1] 

机构地区：[1]中山大学附属第三医院血液科,广州510630

出　　处：《国际内科学杂志》2008年第11期657-661,671,共6页International Journal of Internal Medicine

摘　　要：泛素-蛋白酶体通路是生物体内进行蛋白质选择性降解的重要途径之一,它参与了细胞内许多重要的生理生化过程。蛋白酶体抑制剂可阻断大量调节蛋白的降解,引起细胞内信号系统的紊乱和超负荷,导致细胞生长的抑制,最终使肿瘤进展过程延缓甚至停滞。硼替佐米作为一种蛋白酶体抑制剂,能抑制多发性骨髓瘤细胞的生长及诱导肿瘤细胞的凋亡,同时对血液系统其它恶性肿瘤具有显著作用,并对某些实体瘤也有良好疗效,克服化疗耐药性。本文就蛋白酶体抑制剂硼替佐米在临床上的治疗的研究进展作一综述。The ubiquitin-proteasome pathway is one of important pathways during protein selective degradation in organism which participates in many intracellular physiological and biochemical processes. Proteasome inhibitor can block the degradation of quantity of regulatory proteins and induce intraeellular signal pathway disorder and over loading,which will result in cell growth inhibition as well as the delay and even stop of tumor invasion. As a proteasome inhibitor, Bortezomib can inhibit cell growth of multiple myeloma and induce apoptosis of tumor cells. Further more, it has significant effect on other hematological malignancies, as well as other solid tumors. At the same time, Bortezomib can overcome drug resistance in chemotherapy. This article reviewed studies on therapy with proteasome inhibitor Bortezomib.

关 键 词：蛋白酶体抑制剂 治疗 硼替佐米 

分 类 号：R969[医药卫生—药理学]